Biohaven Ltd. (BHVN)
Biohaven Ltd. is a biopharmaceutical company focused on developing and commercializing innovative medicines for neurological and neuropsychiatric disorders. Known for its research in neuroscience, it has developed treatments targeting conditions such as migraines, neurodegenerative diseases, and other CNS disorders. The company emphasizes scientific innovation and the advancement of therapies to improve patient outcomes.
Company News
Rosen Law Firm is notifying Biohaven Ltd. investors about a securities class action lawsuit alleging false statements regarding drug development prospects for troriluzole and BHV-7000.
Law firm Frank R. Cruz is alerting Biohaven Ltd. investors about an upcoming September 12, 2025 deadline to participate in a securities fraud class action lawsuit, stemming from multiple stock price drops related to drug development setbacks.
Biohaven's stock rose over 6% after the FDA indicated an advisory committee meeting was unnecessary for its New Drug Application for troriluzole, a drug targeting spinocerebellar ataxia. Research suggests this could signal potential drug approval.
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.